DOCSLIB.ORG

J Samuel Pérez-Blanco, Pharm.D, Phd Avda. Licenciado

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
J Samuel Pérez-Blanco, Pharm.D, Phd Avda. Licenciado J Samuel Pérez-Blanco, Pharm.D, PhD Avda. Licenciado Méndez Nieto sn Full Assistant Professor Pharmacokinetics 37003 Salamanca, Spain Tel: +34 677584202 Last update: June 26th, 2019 [email protected] PROFESSIONAL EXPERIENCE Oct 2018 Assistant Professor of pharmacokinetics at Pharmacy and Pharmaceutical Currently Technology, Science Department, University of Salamanca, Spain Application and development of new methodologies of Pharmacokinetic/Pharmacodinamic in approve drugs Pharmacy and Master Degree lecturer Supervision of undergraduate, graduate and PhD students (pharmacokinetics) Jul 2016 Research Scientist in Pharmacometrics Department at Janssen Pharmaceutica Sep 2018 (Johnson & Jonhson), Beerse, Belgium Pharmacokinetic/Pharmacodinamic M&S activities Drug development in clinical phases using mechanistic-based M&S New Drug Approval portfolios (NDA) to regulatory agencies (FDA, EMA, etc.) Oct 2010 Assistant Professor of pharmacokinetics at Pharmacy and Pharmaceutical Jul 2016 Technology, Science Department, University of Salamanca, Spain Research project supervision of pharmacy students in final year Demonstration, seminars and classes of biopharmaceutics & pharmacokinetics Development of education and training material and course organization Virtual training in pharmaceutical care and laboratory inspection (Second Life) Research fields: population pharmacokinetics (model building, evaluation, simulations), therapeutic drug monitoring, analytical methods Nov 2013 Head researcher of pharmacometrics sub-study of GEL-R-COMP 13 clinical Jul 2016 trial (ClinicalTrials.gov Identifier: NCT02012088) Data management and collection (Case Report Form-RedCap) Samples plasma management: samples reception, preservation and quantification (UHPLC-fluorescence detection) Writing of pharmacokinetic sub-study (sampling, popPK & PK/PD analysis) Interdisciplinary meetings, pharmacokinetic formation and consulting Oct 2010 PhD student at Pharmacy and Pharmaceutical Technology Science Department Mar 2016 University of Salamanca, Spain. Title “Clinical pharmacokinetic of doxorubicin in patients diagnosed with non-Hodgkin lymphoma” UHPLC method development and validation (doxorubicin and doxorubicinol) Data management and collection Population pharmacokinetic modelling of doxorubicin and doxorubicinol (metabolite model), simulation and evaluation Presentation of the results in international meetings (PAGE, PKUK, Argentina) Research collaboration in Centre for Applied of Pharmacokinetic Research (CAPKR) University of Manchester, United Kingdom. Oct 14 – Jan 15 Supervisor: Leon Aarons . Monte Carlo simulations and population pharmacokinetic modelling Research collaboration in Torrevieja Hospital, Alicante, Spain. Feb-Apr 2013 Supervisor: Belen Valenzuela . TDM of anticancer drugs, analytical methods, dosing adjustments, population pharmacokinetic with metabolites discussion with hospital clinicians EDUCATION School of Pharmacy, University of Salamanca, Salamanca, Spain 2010-2016 PhD in Pharmacy. Title “Clinical pharmacokinetic of doxorubicin in patients diagnosed with non-Hodgkin lymphoma” 2009-2010 Master´s degree “Design, development and drugs evaluation”. Score: 9.5/10 Specific formations on Pharmacometrics May 2019 Hands-on Experience with Model-informed Drug Development: Incorporating Population Variability into Mechanistic Prediction of PK and Modelling PK/PD [Certara], Kralow (Poland) Apr 2018 The Sheiner and Rowland Advance Course in Pharmacokinetics and Pharmacodynamics, Sils-Maria, Switzerland Nov 2017 Intermediate pharmacokinetic workshop (Malcolm Rowland), Paris (France) LANGUAGES Spanish Mother tongue English Professional, daily use COMPUTER SKILLS / SOFTWARE PK NONMEM, Pirana, PKS (abbott) (advanced), WinNonlin (basic), PhysPK (basic) Scientific R (advanced), SPSS, RefWorks, Papers, Microsoft Office, Zotero TEACHING EXPERIENCE Pharmacy specialist 2012-2016 Course “Drug quantification by HPLC” [campus.usal.es/galenica/hplc] 2011-2016 Course “TDM in Clinical Practice” [http://cursotdmsalamanca.es] Pharmacy degree & Masters Degree 2010-2016 Biopharmaceutics and pharmacokinetics, 3rd year of pharmacy degree 2011-2016 Pharmaceutical care, 4rd year of pharmacy degree 2018-2019 Pharmaceutical Technology, 4rd year of pharmacy degree 2015-2019 Clinic pharmacokinetic of anticancer drugs, students of master degree (cancer) 2018-2019 Preclinical pharmacokinetics studies, students of master degree (drug development) MISCELLANEOUS Date of birth: 01/04/1985 Personal interest: basketball, volleyball, travelling and movies AWARDS 2011 Corresponding Academic - Royal Academy of Medicine and Surgery of Valladolid 2012 Award for the Outstanding Master´s Graduate of the Year 2016 Best research article of 2016, Faculty of Pharmacy, University of Salamanca RESEARCH PROJECTS 2019-2020 Characterization of the therapeutic index of vedolizumab treatment to personalize and optimize pharmacotherapy in patients with ulcerative colitis. Head researcher: Noemí Rebollo. Funding: Sociedad Española de Farmacia Hospitalaria (SEFH) 2019-2020 Determination of cardiovascular risk in community pharmacies. Head researcher: A. Martín Suárez. Funding: Lanzadera universitaria de proyectos con empresas plan TCUE 2018-2020. 2015-2016 Title Contribution to the dose optimization of imatinib to the integral patient treatment diagnosed with myeloid chronic leukaemia. Head researcher: A Sánchez. Funding: Gerencia Regional de Salud de Castilla y León (SACYL) 2014-2015 Title “Population pharmacokinetic of conventional and liposome doxorubicin in patients diagnosed with lymphoma: cardiotoxicity evaluation. Head researcher: MJ Garcia. Funding: University of Salamanca, Spain 2012-2014 Title “Physiological models as a tool in translational and individualised medicine in the therapeutic pharmacology field”. Head researcher: A Sánchez Navarro. Funding: Junta de Castilla y León, Spain PUBLICATIONS Eva María Sáez Fernández*, Jonás Samuel Pérez-Blanco*, José M Lanao, M Victoria Calvo & Ana Martín-Suárez (2019) Evaluation of renal function equations to predict amikacin clearance, Expert Review of Clinical Pharmacology, DOI: 10.1080/17512433.2019.1637253; *Contributed equally as first author. Martin-Suarez A, Sanchez-Hernandez JG, Medina-Barajas F, Pérez-Blanco JS, Lanao JM, Garcia-Cuenllas Alvarez L, Calvo MV. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia. Expert Rev Clin Pharmacol. 2017 Aug;10(8):911-917. doi: 10.1080/17512433.2017.1344096 Pérez-Blanco, J.S., Santos-Buelga, D., Fernández de Gatta, M., Hernández-Rivas, J., Martín, A. and García, M. (2016). Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. British Journal of Clinical Pharmacology. DOI: 10.1111/bcp.13070 Pérez-Blanco JS, del Mar Fernández de Gatta M, Hernández-Rivas JM, Sánchez MJG, Marinero MLS, López FG. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 1;955- 956:93–7 García-Peñalvo FJ, Cruz-Benito J, Maderuelo C, Pérez-Blanco JS, Martín-Suárez A. Usalpharma: A Cloud-Based Architecture to Support Quality Assurance Training Processes in Health Area Using Virtual Worlds. Sci World J. 2014, Article ID 659364, 10 pages, 2014. doi: 10.1155/2014/659364 Maderuelo, C; Martin-Suarez, A; Pérez-Blanco, JS; Zazo, H; Cruz-Benito, J; Domínguez-Gil, A. Facility-based inspection training in a virtual 3D-laboratory. Acred Qual Assur. 2014, Vol. 19,403-09. doi: 10.1007/s00769-014-1065-44 COMMUNICATIONS ORAL Pérez-Blanco JS, Santos Buelga D, Hernández Rivas JM, Fernández de Gatta MM, García MJ. Modelo farmacocinético poblacional de doxorrubicina y doxorrubicinol en pacientes diagnosticados de linfoma no Hodgkin. 6th Jornadas de Modelización y Simulación en Biomedicina, Madrid, España, Nov 2015 Pérez-Blanco JS, Mangas V. Covariate model building: GAM & SCM. 3rd Workshop en Modelización Farmacocinética y Farmacodinámica, Barcelona, Spain, Nov 2014 Pérez-Blanco JS. Population pharmacokinetic of doxorubicin and doxorubicinol in haematological patients. 4rd Uppsala Pharmacometric Summer School, Uppsala, Sweden, Aug 2014 POSTER Carlos Pérez-Ruixo*, Jonás Samuel Pérez-Blanco*, Caly Chien, Margaret Yu, Daniele Ouellet, Juan-José Pérez-Ruixo, Oliver Ackaert. Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects. Population Approach Group of Europe meeting 28 (2019), Stockholm, Sweeden. [abstract=8984]; *Contributed equally as first author. Alberto Russu, Jonás Samuel Pérez-Blanco, Peter Van Der Ark, Vikash Sinha, Adam Savitz, Peter De Boer, Jay B. Saoud, Partha Nandy, Juan Jose Perez Ruixo. Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist. XXVI meeting of Population Approach Group of Europe (PAGE). Budapest, Hungría, 6-9 de Junio de 2017 (Internacional). ISSN 1871-6032. PAGE 26 (2017) Abstr 7366 [abstract=7366] Sánchez JG, Medina FP, Martín-Suárez A, Pérez-Blanco JS, Lanao JM, Calvo MV. Pharmacokinetics of digoxin during pregnancy. 44th ESCP Symposium on clinical pharmacy. Lisbon, Portugal, Oct 2015 Pérez-Blanco JS, Santos Buelga D, Hernández Rivas JM, Fernández de Gatta MM, García MJ. Modelo farmacocinético poblacional de doxorrubicina y doxorrubicinol
Load more

Recommended publications
  • The Role of Modelling and Simulation in Drug Development
    The Role of Modelling and Simulation in Drug Development Leon Aarons Manchester Pharmacy School The University of Manchester Plan • Overview • Role of modelling in Phase I drug development • Role of modelling in the development of anti- cancer agents • Summary Models The type of model to be developed should be driven by the available information and the goal of the simulations Category Information Goal needed Explanatory Rich Extrapolation in complex and Mechanistic variable environment models Semi-mechanistic models Empirical Interpolation in Descriptive models “Poor” simple and stable environment Days Months Years 100 10 12tt C() t C12 e C e 1 concentration 0.1 0.01 0 2 4 6 8 10 time k12 1 2 k21 k10 dC() t V1 kVCt()()() kVCt kVCt 1dt 1211 1011 2122 dC() t V2 k V C()() t k V C t 2dt 12 1 1 21 2 2 PBPK MODEL dC() t KpV out, H QCtQC ()().() tCLKpC t H Hdt H A H out, H int H out , H Role of Modelling and Simulation in Phase I Drug Development L. Aarons, M. Karlsson, F. Mentré, F. Rombout, J.-L. Steimer, A. van Peer COST B15 Brussels January 10-11, 2000 Eur.J.Pharm.Sci. 13, 115-122 (2001) COST European COoperation in the Field of Scientific and Technical Research Definition of Phase I • Phase I is the transition Phase from preclinical to clinical evaluation •Learning process primarily focused on: - Safety (Tolerability) - PK/PD - Metabolism - Potential interactions (drugs/food) - Dosage form development (equivalence) Phase I Safety ¥ Tolerability Data • FIM and S/MD study wide dose range • Escalation design • Healthy subjects
    [Show full text]
  • Real Projects with Real Impacts Dave Handelsman, Project Data Sphere, LLC, Cary, NC, USA
    PhUSE US Connect 2019 Paper AB06 The Power of Data Sharing: Real Projects with Real Impacts Dave Handelsman, Project Data Sphere, LLC, Cary, NC, USA ABSTRACT Data sharing leading to improved cancer patient outcomes provides exciting examples of applying Big Data and Analytics to clinical research. Since 2014, Project Data Sphere has aggregated patient-level data from more than 135,000 patients spanning 150 trials, and made this data available for exploration and investigation to more than 2,000 researchers. This successful data sharing program has enabled medically relevant insights to be discovered and published in leading peer-accepted journals, and new research programs are underway, including: • Development of an external control arm for small cell lung cancer that may eliminate the need to enroll cancer patients in standard-of-care comparator treatment arms • Development of machine learning tools for tumor image processing • Investigations into rare but serious adverse events associated with new of immuno-oncology therapies In this session, the opportunities and challenges of clinical trial data sharing will be discussed as they relate to Big Data and Analytics. INTRODUCTION Data sharing has broad meaning, even when discussed in the context of clinical research. Depending on the context, this concept can refer to the sharing of patient-level data traditionally associated with clinical trials, or it can alternatively (or additionally) refer to less traditional data types such as genomics and images, and can also refer to data extracted from electronic health records. For the purposes of this paper, data sharing will be discussed in the context of data made available from completed clinical trials.
    [Show full text]
  • Hierarchical Mechanistic Modelling of Clinical Pharmacokinetic Data
    Hierarchical mechanistic modelling of clinical pharmacokinetic data A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Medical and Human Sciences 2015 Thierry Wendling Manchester Pharmacy School Contents List of Figures ........................................................................................................ 6 List of Tables .......................................................................................................... 9 List of abbreviations ............................................................................................ 10 Abstract ................................................................................................................ 13 Declaration ........................................................................................................... 14 Copyright ............................................................................................................. 14 Acknowledgements .............................................................................................. 15 Chapter 1: General introduction ...................................................................... 16 1.1. Modelling and simulation in drug development ........................................ 17 1.1.1. The drug development process .......................................................... 17 1.1.2. The role of pharmacokinetic and pharmacodynamic modelling in drug development ..................................................................................................
    [Show full text]
  • Drug Structure–Transport Relationships
    J Pharmacokinet Pharmacodyn (2010) 37:541–573 DOI 10.1007/s10928-010-9174-0 Drug structure–transport relationships Michael S. Roberts Received: 10 August 2010 / Accepted: 22 October 2010 / Published online: 24 November 2010 Ó The Author(s) 2010. This article is published with open access at Springerlink.com Abstract Malcolm Rowland has greatly facilitated an understanding of drug structure–pharmacokinetic relationships using a physiological perspective. His view points, covering a wide range of activities, have impacted on my own work and on my appreciation and understanding of our science. This overview summarises some of our parallel activities, beginning with Malcolm’s work on the pH control of amphetamine excretion, his work on the disposition of aspirin and on the application of clearance concepts in describing the disposition of lidocaine. Malcolm also spent a considerable amount of time developing principles that define solute structure and transport/pharmacokinetic relationships using in situ organ studies, which he then extended to involve the whole body. Together, we developed a physiological approach to studying hepatic clearance, introducing the convection–dispersion model in which there was a spread in blood transit times through the liver accompanied by permeation into hepatocytes and removal by metabolism or excretion into the bile. With a range of colleagues, we then further developed the model and applied it to various organs in the body. One of Malcolm’s special interests was in being able to apply this knowledge, together with an understanding of physiological differences in scaling up pharmacokinetics from animals to man. The description of his many other activities, such as the development of clearance concepts, application of pharmacokinetics to the clinical situation and using Based on an invited presentation at the European Pharmaceutical Sciences Meeting: Pharmacokinetics: Spearheading advances and delivering the science (on the occasion of Professor Malcolm Rowland’s 70th birthday) London, October 5, 2009.
    [Show full text]
  • Page | 1 Tuesday 7 June 14:00-18:00 Registration at the Conference
    Tuesday 7 June 14:00-18:00 Registration at the Conference Venue 19:30-21:00 Welcome reception Wednesday 8 June 08:00-08:45 Registration 08:45-09:00 Welcome and Introduction Chair: Oscar Della Pasqua, 09:00-10:20 Immune response to drug treatment and immunotherapy Dinesh De Alwis A biological perspective on immune response to drug treatment 09:00-09:40 Nigel Klein (intended and unintended effects) Intricate PK and PD for the novel immunocytokine CEA-IL2v and their 09:40-10:00 Hans Peter Grimm pre-clinical to clinical translation Investigation of anti-CTLA-4 immuno-oncology therapy through a 10:00-10:20 Kirill Peskov quantitative systems pharmacology model 10:20-11:40 Coffee break, Poster and Software session I Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 11:40-12:20 Systems pharmacology Chair: Charlotte Kloft 11:40-12:00 Kapil Gadkar A Six-Stage Workflow for Robust Application of Systems Pharmacology The zebrafish as model for translational systems pharmacology: 12:00-12:20 Rob van Wijk expanding the allometric scale in vertebrates with five orders of magnitude 12:20-13:50 Lunch Chair: Leon Aarons, Shasha 13:50-15:05 Growth (I) Jumbe Introduction to the Gates' Healthy Birth, Growth & Development 13:50-14:05 Shasha Jumbe knowledge integration project 14:05-14:45 Louise Ryan Trajectory modelling based on early childhood longitudinal growth data Page | 1 Determinants for physical growth patterns in low- and middle-income 14:45-15:05 Niclas Jonsson countries 15:05-15:10 Announcement of WCoP 2016
    [Show full text]
  • Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin
    The AAPS Journal ( # 2016) DOI: 10.1208/s12248-016-9965-3 Research Article Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin Andrés Olivares-Morales,1,2,5 Avijit Ghosh,3 Leon Aarons,1 and Amin Rostami-Hodjegan1,4 Received 27 April 2016; accepted 21 July 2016 Abstract. A new minimal Segmented Transit and Absorption model (mSAT) model has been recently proposed and combined with intrinsic intestinal effective permeability (Peff,int) to predict the regional gastrointestinal (GI) absorption (fabs) of several drugs. Herein, this model was extended and applied for the prediction of oral bioavailability and pharmacoki- netics of oxybutynin and its enantiomers to provide a mechanistic explanation of the higher relative bioavailability observed for oxybutynin’s modified-release OROS® formulation compared to its immediate-release (IR) counterpart. The expansion of the model involved the incorporation of mechanistic equations for the prediction of release, transit, dissolution, permeation and first-pass metabolism. The predicted pharmacokinetics of oxybutynin enantiomers after oral administration for both the IR and OROS® formulations were in close agreement with the observed data. The predicted absolute bioavailability for the IR formulation was within 5% of the observed value, and the model adequately predicted the higher relative bioavailability observed for the OROS® formulation vs. the IR counterpart. From the model predictions, it can be noticed that the higher bioavailability observed for the OROS® formulation was mainly attributable to differences in the intestinal availability (FG) rather than due to a higher colonic fabs, thus confirming previous hypotheses. The predicted fabs was almost 70% lower for the OROS® formulation compared to the IR formulation, whereas the FG was almost eightfold higher than in the IR formulation.
    [Show full text]
  • Curriculum Vitae
    Curriculum Vitae PERSONAL INFORMATION Leon Aarons WORK EXPERIENCE March 1976- Present Professor The University of Manchester (United Kingdom) Researcher and teacher in the areas of pharmacokinetics and pharmacodynamics EDUCATION AND TRAINING September 1971-December 1973 PhD The University of Manchester (United Kingdom) PhD in Theoretical Chemistry ADDITIONAL INFORMATION Expertise Pharmacokinetic and pharmacodynamic modelling; population pharmacokinetic modellingt; optimal design of pharmacokinetic and pharmacodynamic clinical trials; physiologically based pharmacokinetic modelling; drug absorption modelling Publications S.Y.A. Cheung, T. Rodgers, L. Aarons, I. Gueorguieva, G.L. Dickinson, S. Murby, C. Brown, B. Collins, M. Rowland, Whole body physiologically based modelling of -blockers in the rat: events in tissues and plasma following an i.v. bolus dose, Br J Pharmacol DOI:10.1111/bph.14071 (2017). Y.T. Patel, V.M. Daryani, P. Patel, D. Zhou, J. Fangusaro, D.J. Carlile, P.D. Martin, L Aarons, C.F. Stewart, 'Population pharmacokinetics of selumetinib and its metabolite N-desmethyl-selumetinib in adult patients with advanced solid tumors and children with low-grade gliomas CPT Pharmacometrics Syst Pharmacol 6, 305-314 (2017). S.C. Goulooze, S. Völler, P.A.J. Völitalo, E.A.M. Calvier, L. Aarons, E.H.J. Krekels, C.A.J. Knibbe, The influence of normalization weight in population pharmacokinetic covariate models, Clin Pharmacokinet DOI:10.1007/s40262-018-0652-7 (2018). C. Imholt,| T. Abdulla,| A. Stevens,| P. Edwards,| J. Jacob, D. Woods, E. Rogers, L. Aarons, D. Segelcke, Establishment and validation of microsampling techniques in wild rodents for ecotoxicological research, Appl Toxicol DOI: 10.1002/jat.3635 (2018). E.C.
    [Show full text]
  • PBPK) Models of Methyl-Tertiary Butyl Ether (MTBE
    ABSTRACT SMITH, NIKKI SHAVON. A Comparison of Physiologically-Based Pharmacokinetic (PBPK) Models of Methyl-Tertiary Butyl Ether (MTBE). (Under the direction of Hien T. Tran and Marina V. Evans.) Methyl-tertiary-butyl ether (MTBE) is a gasoline additive that gained widespread use after the passage of the Clean Air Act Amendments of 1990 designed to help reduce urban air pollution and toxic air emissions. Reports of water contamination and adverse health affects from inhalation exposure to MTBE also grew. We review MTBE carcinogenicity studies conducted in rodents and complete physiologically-based pharmacokinetic (PBPK) inhalation model comparisons, parameter estimation, and an assessment of design elements that help fit available human data. PBPK models are mathematical constructs that consider different organs and tis- sues as compartments and make it possible to obtain a quantitative characterization of concentration-time profiles in the respective compartments. We specifically test a hypothesis whether complexity should be added to the lung compartment for substances with a large blood:air partition coefficient. Further, since rats exposed to MTBE exhibited renal tumors, we consider metabolism as a mode of action for that endpoint and we include a kidney metabolism pathway, which is generally not used in PBPK models, in our model. Finally, we use sensitivity analysis and model validation and comparison techniques to assess the lung complexity hypothesis, draw conclusions about the inclusion of the kidney metabolism pathway, and drive model design iterations by removing parameters, and thus, metabolism pathways that are not significant to the models’ results. Initial model analysis outcomes indicate that model simplicity prevails and adding lung complexity for the test case high blood:air partition coefficient substance (in this case MTBE’s metabolite, tert-Butyl-alcohol) is not desirable.
    [Show full text]
  • Modelling the Genesis and Treatment of Cancer: the Potential 5 Role of Physiologically Based Pharmacodynamics
    EUROPEANJOURNALOFCANCER46 (2010) 21– 32 available at www.sciencedirect.com journal homepage: www.ejconline.com Position Paper Modelling the genesis and treatment of cancer: The potential 5 role of physiologically based pharmacodynamics Jean-Louis Steimer a, Svein G. Dahl b, Dinesh P. De Alwis c, Ursula Gundert-Remy d, Mats O. Karlsson e, Jirina Martinkova f, Leon Aarons g,*, Hans-Ju¨ rgen Ahr h, Jean Clairambault i, Gilles Freyer j, Lena E. Friberg e, Steven E. Kern k, Annette Kopp-Schneider l, Wolf-Dieter Ludwig m, Giuseppe De Nicolao n, Maurizio Rocchetti o,In˜ aki F. Troconiz p a Novartis Pharma AG, Basel, Switzerland b Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Norway c Eli Lilly & Company, Surrey, UK d Bundesinstitut fu¨ r Risikobewertung, Berlin, Germany e Uppsala University, Uppsala, Sweden f Charles University of Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic g University of Manchester, Manchester, United Kingdom h Bayer Health Care, Leverkusen, Germany i INRIA, Paris, France j Medical Oncology Unit, Centre Hospitalier Lyon-Sud, Pierre-Be´nite, France k College of Pharmacy, University of Utah, USA l Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany m Robert-Ro¨ssle-Klinik Oncology and Tumorimmunology, Berlin-Buch, Germany n Department of Computer Engineering and Systems Science, University of Pavia, Pavia, Italy o Accelera, Milan, Italy p Departamento de Farmacia y Tecnologı´aFarmace´utica, University Navarra, Pamplona, Spain ARTICLE INFO ABSTRACT Article history: Physiologically based modelling of pharmacodynamics/toxicodynamics requires an a priori Received 16 April 2009 knowledge on the underlying mechanisms causing toxicity or causing the disease.
    [Show full text]
  • Population Modelling
    ® 1999 Elsevier Science B.V, All rights reserved. Variability in Human Drug Response 239 G.T. Tucker, Editor Population Modelling Leon Aarons School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, U.K. ABSTRACT Frequently dosing recommendations that emerge from a clinical drug development program are found inappropriate and when individual dose adjustment is needed, the recommendations provided may not be informative enough to allow the adjustment to be undertaken in an optimal manner. Frequently, and particularly in the later stages of drug development, only relatively sparse observational concentration and effect data are available. Recently developed statistical methods offer the possibility of gaining integrated information on pharmacokinetics and response from such data, obtained directly in patients who are being treated with the drug under development. The methods allow the incorporation of data from patient groups which are often excluded from classically designed clinical trials and also the analysis of a variety of unbalanced designs that frequently arise in the evaluation of dose or concentration- efficacy and -safety profiles, which do not readily lend themselves to other forms of statistical analysis. The analysis of sparse observational data, which is called the population approach, has been implemented in phase in studies to obtain additional information about the PK/PD model. However, the primary purpose of phase III clinical trials generally is not PK/PD and consequently population PK/PD studies must be carefully interwoven with existing protocols. Key words: drug development, pharmacokinetics, pharmacodynamics, sparse data. Correspondence: Leon Aarons, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, U.K., Tel: 444-161-275-2357, Fax: +44-161-275-2396, Email: [email protected] INTRODUCTION Pharmacokinetics, from the literal Greek meaning of the name, is the study of drug movement in the body.
    [Show full text]
  • A Workshop, Presenting the Basic Concepts and Applications of Pharmacokinetics in the Pharmaceutical, Clinical, and Veterinary S
    A 5-day Workshop, taught by leading experts, MAIN ORGANISER APPLICATION FORM presenting the basic concepts of pharmacokinetics with pharmaceutical and clinical applications. MALCOLM ROWLAND or apply online www.pkworkshops.com For Whom Intended Pharmaceutical scientists, Malcolm Rowland is Professor Emeritus Name _________________________________ pharmacologists and other scientists, pharmacists, and (Pharmacy), and member, Centre for Applied (Dr/Ms/Mr/..) First name Surname/Family name physicians wishing to understand and apply Pharmacokinetic Research, University of pharmacokinetic principles in drug selection, drug Manchester, England. His main research interests development, protocol design, drug evaluation, drug are in the physiological basis of pharmacokinetics Occupation registration and in the establishment of dosage and its application to drug discovery, development ___________________________________________ regimens. Emphasis is placed on relating pharmaco- and use. He is the author of over 300 research Institution or Company kinetics to underlying physiological processes, with a articles, reviews and book chapters. Together with ___________________________________________ brief introduction to pharmacodynamics. Only Dr. T.N. Tozer, Professor Rowland has written Department limited exposure to pharmacokinetics is assumed. Introduction to Pharmacokinetics and ___________________________________________ Workshop Content The Workshop is divided into Pharmacodynamics: The Quantitative Basis of lectures and associated small group workshops,
    [Show full text]
  • Page | 1 Tuesday June 10 18.30-20.00 Registration at The
    Tuesday June 10 18.30-20.00 Registration at the Cruise Terminal 20.30-22.30 Welcome reception at the Santísima Trinidad located in front of Hotel Melia Wednesday June 11 08:00-08:45 Registration 08:45-09:00 Welcome and Introduction Chair: Leon Aarons and Panos 09:00-10:20 OrBiTo and Mechanistic absorption modelling Macheras Amin Rostami- OrBiTo - translating mechanistic knowledge on absorption into predictive 09:00-09:40 Hodjegan models Benjamin Mechanism-based modelling of gastric emptying and bile release in response 09:40-10:00 Guiastrennec to caloric intake Andrés An in silico physiologically-based pharmacokinetic (PBPK) study of the impact 10:00-10:20 Olivares- of the drug release rate on oral absorption, gut wall metabolism and relative Morales bioavailability 10:20-11:50 Coffee break, Poster and Software session I Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 11:50-12:40 Facilitating Modelling and Simulation Chair: Charlotte Kloft Development of Virtual Population for a Quantitative Systems Pharmacology 11:50-12:10 Kapil Gadkar model 12:10-12:30 Maciej Swat PharmML 1.0 – An Exchange Standard for Models in Pharmacometrics Marc 12:30-12:40 Proposal for a Web-Based Open Pharmacometrics Curriculum Gastonguay 12:40-14:10 Lunch 14:10-15:10 Model-based individualisation Chair: Nick Holford Pierre 14:10-14:50 Implementing model-based individualization in the clinic Marquet Page | 1 Núria Buil A step forward toward personalised medicine in oncology: Population 14:50-15:10 Bruna modelling for
    [Show full text]